Announcement PDF ASX ANNOUNCEMENT Manufacturing Milestones and New Head Office    Rapid scale-up of RECCE® 327 manufacture (non-GLP) successfully achieved at Perth facility Perth laboratory upgrade to GLP standard now in progress Corporate head office, and facility for pilot-plant established in Sydney Sydney, New South Wales, 28 July 2016 – Recce Ltd (ASX: RCE), the developer of a new class of patented drugs targeted at antibiotic, anti-cancer and anti-viral human applications, is pleased to announce key manufacturing achievements and establishment of a new Head Office, in support of its IND application and anticipated future human trials. 1. Perth Activities Recce has moved quickly to rapidly scale-up production (non-GLP) of RECCE® 327 at its Perth facilities. Pleasingly, and in support of Recce’s highly economical method of manufacture, more than 9 litres of RECCE® 327 was produced in-house, over the last week – in order to complete non-GLP pre-clinical studies for Investigational New Drug (IND) application to USA regulator the Food & Drug Administration (FDA). Dr Graham Melrose (Executive Chairman) & Michael Aarons (Laboratory Manager) with 500 mL of RECCE® 327 Recce is now recruiting a chemist with GLP-compliance experience to assist in upgrading Perth’s laboratory for the purposes of producing GLP-certified product. This is an important part of the pre-clinical process as the FDA demands that the systems and processes to create the product used in the final preclinical tests and potential human trials are reproducible and safe. 2. Sydney Activities In support of Recce’s focus on its activities on the East Coast of Australia, Recce has successfully established a small but important Head Office at L34, 50 Bridge Street Sydney. Recce has leased property in Macquarie (Technology) Park – Australia’s leading pharmaceutical hub – in order to develop a pilot-plant facility for the manufacture of RECCE® 327 for anticipated future human trials. Recce's Pilot Plant facility (Macquarie Park, Sydney) At the above 64 Talavera Road, Macquarie Park facility (surrounded by the World’s leading PharmCos), Recce’s manufacturing process that has proven to be economic and reproducible, will be automated within a pilot plant for the rapid production of RECCE® 327. Initial plans to locate this facility in Boston USA, the world’s busiest pharmaceutical hub, have been deferred following the agent’s inability to consummate an agreed lease in the highly competitive laboratory real estate market. This was disappointing due to the opportunities available in the USA, but has not delayed nor negatively impacted Recce’s IND application to the FDA in the USA. Recce’s establishment of premises on the East Coast of Australia has seen Mr James Graham, Executive Director and responsible for corporate and marketing developments take up duties permanently at the CBD address – the location of Recce’s future board meetings, with Eastern States based newly-appointed Non-Executive Directors Ms Bernadette Murdoch (Marketing Expert and PharmCo Executive) and Dr Dominic Barnes (Medical Practitioner and Pharmaceutical Expert). Dr Graham Melrose, Executive Chairman commented, “These exciting developments position Recce well to fully capitalise on the many opportunities for its technology.” For further information please visit www.recce.com.au or contact: Investor Relations Peter Williams CFO & Company Secretary Recce Ltd Tel: +61 8 9253 9800 Media Communication Karen Oswald - karen.oswald@markocommunications.com.au Gary Buchholz – gary@markocommunications.com.au Marko Communications Tel: +61 423 602 353 About Recce Ltd Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327. The discovery of RECCE® 327’s capabilities against cancer and viruses (as well as bacteria-superbugs) has greatly increased the value of the Company’s technology, especially in view of the synergism between antibiotic/anti-cancer properties and anti-viral/anti-cancer properties. Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies and potential financial returns from manufacture and distribution in about 80% of the world’s pharmaceutical markets. To receive the latest information on Recce - Subscribe here